FamiCord AG (FRA:V3V)

Germany flag Germany · Delayed Price · Currency is EUR
4.530
0.00 (0.00%)
Last updated: Apr 24, 2026, 5:35 PM CET
Market Cap78.97M +19.2%
Revenue (ttm)88.29M +9.5%
Net Income-9.80M
EPS-0.58
Shares Outn/a
PE Ration/a
Forward PE65.80
Dividendn/a
Ex-Dividend Daten/a
Volume26
Average Volume226
Open4.600
Previous Close4.530
Day's Range4.530 - 4.600
52-Week Range3.640 - 7.650
Betan/a
RSI28.76
Earnings DateApr 30, 2026

About FamiCord AG

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the compa... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1997
Employees 771
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol V3V

Financial Performance

In 2024, FamiCord AG's revenue was 82.18 million, an increase of 6.65% compared to the previous year's 77.06 million. Losses were -12.14 million, 550.7% more than in 2023.

Financial Statements

News

Vita 34 & FamiCord AG: 2025 Preliminary Results & 2026 Outlook

FamiCord reports solid 2025 results and cautious 2026 guidance, balancing efficiency gains with softer demand and rising geopolitical and macroeconomic risks.

9 days ago - Wallstreet:Online